ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

VCYT Veracyte Inc

23.93
-1.35 (-5.34%)
After Hours
Last Updated: 21:02:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Veracyte Inc NASDAQ:VCYT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.35 -5.34% 23.93 23.47 24.39 25.67 23.51 24.90 876,835 21:02:11

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

17/07/2024 10:00pm

Business Wire


Veracyte (NASDAQ:VCYT)
Intraday Stock Chart


Thursday 18 July 2024

Click Here for more Veracyte Charts.

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BIbb7f6b70b4ce4820b6391059390d6139

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Investors: Shayla Gorman investors@veracyte.com (619) 393-1545

Media: Tracy Morris media@veracyte.com (650) 380-4413

1 Year Veracyte Chart

1 Year Veracyte Chart

1 Month Veracyte Chart

1 Month Veracyte Chart